Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.

Journal Article (Journal Article)

Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR <140 versus ≥140 overall (median: 6.4 vs 5.9 years; hazard ratio: 0.9; 95% CI: 0.7-1.2). A ≥25% decrease in PLR at week 4 overall was associated with longer DFS versus no change (hazard ratio: 0.8; 95% CI: 0.6-1.0). Conclusion: Baseline PLR was not prognostic for DFS with adjuvant sunitinib treatment in patients with renal cell carcinoma. Clinical Trials Registration: NCT00375674 (ClinicalTrials.gov).

Full Text

Duke Authors

Cited Authors

  • Patel, A; Ravaud, A; Motzer, RJ; Pantuck, AJ; Staehler, M; Escudier, B; Martini, J-F; Lechuga, M; Lin, X; George, DJ

Published Date

  • February 2021

Published In

Volume / Issue

  • 17 / 4

Start / End Page

  • 403 - 409

PubMed ID

  • 33028084

Pubmed Central ID

  • PMC8488532

Electronic International Standard Serial Number (EISSN)

  • 1744-8301

Digital Object Identifier (DOI)

  • 10.2217/fon-2020-0652


  • eng

Conference Location

  • England